The current first‐line pharmacological treatment for PD is oral l‐dopa, but clinical response declines with progression of disease as more dopaminergic neurons degenerate and levels of AADC enzyme (required for the conversion of l‐dopa to dopamine) (Fig. 1) decline. The gene discussed is DDC; the disease is Parkinson disease.